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Abstract
Objectives: To study the diagnostic delay for pituitary stalk interruption syndrome (PSIS) with growth hormone deficiency
(GHD) and the sensitivity of the auxological criteria of the Growth Hormone Research Society (GHRS) consensus guidelines.
Methods: A single-center retrospective case-cohort study covering records from January 2000 through December 2007
evaluated the performance of each GHRS auxological criterion for patients with GHD and PSIS. Diagnostic delay was
calculated as the difference between the age at which the earliest GHRS criterion could have been observed and the age at
diagnosis of PSIS with GHD. A diagnostic delay exceeding one year was defined as late diagnosis.
Results: The study included 21 patients, 16 (76%) of whom had isolated GHD and 5 (24%) multiple pituitary hormone
deficiencies. The median age at diagnosis was 3.6 years (interquartile range, IQR, 2.6–5.5). The median diagnostic delay was
2.3 years (range 0–12.6; IQR 1.5–3.6), with late diagnosis for 17 patients (81%). Height more than 1.5 SDS below target
height was the most effective criterion: 90% of the patients met the criterion before diagnosis at a median age of 1 year,
and it was the first criterion to be fulfilled for 84%.
Conclusion: In our cohort, the delay for diagnosis of PSIS with GHD was long and could have been reduced by using the
GHRS criteria, in particular, height more than 1.5 SDS below the target height. The specificity of such a strategy needs to be
tested in healthy populations.
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Introduction
Growth hormone (GH) deficiency (GHD) can be congenital or
acquired. The incidence of congenital GHD has been assessed
at from 1/4000 to 1/10 000 [1,2,3,4]. The pituitary stalk inter-
ruption syndrome (PSIS) is a sign of congenital and permanent
GHD [5,6,7]. It is diagnosed by magnetic resonance imaging
(MRI) and includes the absence of both a visible pituitary stalk and
normal posterior lobe hyperintense signals in the sella turcica,
together with the presence of a hyperintense nodule in the region
of the infundibular recess of the third ventricle. Familial forms of
PSIS and associated malformations suggest that its origin is
antenatal [8]. It is important to diagnose GHD and start treatment
as soon as possible because this deficiency is associated with excess
mortality and substantial morbidity [9,10]. Moreover, because
insufficient height at the onset of puberty leads to short final
height, early diagnosis and treatment of GHD are necessary to
allow catch-up growth to optimal height before puberty [11]. Signs
of congenital GHD in neonates include hypoglycemia, prolonged
jaundice, and microphallus [1,8,12,13]. In older children, the
diagnosis is based on short stature or growth failure. Height for age
is the most common criterion for referral for GH evaluation [14].
However, the mean ages reported for diagnosis of symptomatic
PSIS in various studies range from 4 to 9 years and suggest
important diagnostic delay [5,7,12,13,15].
In 2000, the GH Research Society (GHRS) published
guidelines based on height for age but also five other auxological
criteria (see below), to ensure that children and adolescents with
GHD are appropriately identified and treated [16]. A survey has
shown that these criteria are not currently applied, probably
because the concomitant use of six auxological criteria might be
difficult in day-to-day routine practice [14]. Moreover the
performance (notably sensitivity for early diagnosis) of these
guidelines has never been tested.
The objective of this study was therefore to study the diagnostic
delay for PSIS with GHD and the sensitivity of the auxological
criteria of the GHRS to identify the most useful ones and simplify
their routine use.
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Characteristics of the population
During the study period, 67 patients seen for growth failure had
PSIS and/or GHD: 38 (57%) had GHD with a normal MRI or an
isolated hypoplastic anterior pituitary gland, 2 (3%) had GHD and
PSIS but had been adopted, six (9%) patients had GHD and PSIS
diagnosed in the neonatal period. The study thus included 21
(31%) patients with GHD and PSIS (Table 1), 76% of them boys.
One patient was born preterm, and nine were delivered by
cesareans (43%) (confidence interval, CI=22–64), including three
in breech presentation. One patient had midline abnormalities,
including bilateral optic nerve hypoplasia.
Median age at diagnosis was 3.6 years (range 1–13.6;
interquartile range IQR: 2.6–5.5), and all patients were prepu-
bertal (Table 1). Sixteen patients (76%) (95%) (CI 58–94) had
isolated GHD and five (24%) (CI 6–42) had multiple pituitary
deficiencies (MPD) with thyroid stimulating hormone deficiency
in four and adrenocorticotrophin deficiency in two. The median
height was 22.5 SDS (range 24.3; 21.3) (IQR 23.5; 22) and
median BMI 20.23 SDS (range 23.7; 4) (IQR 21.1; 0.5). The
median height velocity was 23.1 SDS (range 24.2; 0.3) (IQR
23.4; 21.6).
Medical and growth history
Nine families (43%) (CI 22–64) first consulted a private-practice
pediatrician about growth failure, and 12 families an outpatient
pediatric department (57%) (CI 36–78). One family sought care
directly from our team. Eleven patients (52%) (CI 31–73) had
undergone laboratory testing for growth retardation before
consulting our team, two had had a GH stimulation test, and 3
had had serum IGF-1 measured. Both GH stimulation tests were
normal, and serum IGF-1 was less than –2 SDS, but no further
diagnostic procedures were performed to rule out GHD. The
patient with bilateral optic nerve hypoplasia had had neonatal
hypoglycemia and microphallus but was not evaluated for GH
secretion until the age of one year, and then for growth failure. His
pediatrician had ordered an MRI at 2 months of age because his
eyes were not yet following objects. At 5 months of age, his growth
rate started to decrease and at one year of age, he was addressed to
our department for growth retardation. The PSIS diagnosis was
based on the MRI performed at 2 months of age.
No episodes of severe hypoglycemia or adrenal crisis were
observed before diagnosis, and no child had any neurological
deficiency.
Performance of GHRS criteria
Table 2 summarizes the performance of each GHRS criterion.
The criterion of height more than 2 SDS below the mean + height
velocity over 1 year more than 1 SDS below the mean for
chronological age had a frequency at final diagnosis of 100%.
Height more than 1.5 SDS below the target height was the most
effective criterion: 90% of the patients had met the criterion before
diagnosis, at a median age of 1 year (range 0; 9) (IQR 0.5; 1.8),
and it was the first criterion to be met for 84% of the patients. Its
use could have reduced diagnostic delay by 2.1 years (range 0;
12.6) (IQR 1.5; 2.9). The combined use of these two criteria,
height more than 2 SDS below the mean + height velocity over 1
year more than 1 SDS below the mean for chronological age and
height more than 1.5 SDS below the target height, might also have
reduced diagnostic delay by 2.1 years (range 0; 12.6) (IQR 1.5; 3)
for a median age at first validation of one of these criteria, that is,
the first visit at which a doctor could have determined that the
criterion had been met, was 1 year (range 0; 4.7) (IQR 0.6; 2).
Late Diagnosis
Median age at diagnosis was 3.6 years (range 1; 13.6) (IQR 2.6;
5.5). Median age when the auxological criterion was met was 1 year
(range 0; 4) (IQR 0.6; 2). The median diagnostic delay was 2.3 years
(range 0; 12.6) (IQR 1.5; 3.6), with late diagnosis in 17 patients (81%).
Table 1. Patient characteristics.
Isolated GHD (n=16) MPD (n=5) TOTAL (n=21)
Neonatal symptoms n’ Percentage n’ Percentage n’ Percentage
Breech delivery 2 12.5% (CI 0–29) 1 20% (CI 0–55) 3 14% (CI 0–29)
Cesarean delivery 5 31% (CI 8–54) 4 80% (CI 45–100) 9 43% (CI 22–64)
At diagnosis Median (range) Median (range) Median (range)
Age (yr) 16 3.2 (1; 13.6) (IQR 2.6; 4.9) 5 5.1 (1; 10.5) (IQR 5; 5.6) 21 3.6 (1; 13.6) (IQR 2.6; 5.5)
Bone age (yr) 12 1.5 (0.5; 9.5) (IQR 1.2; 2.3) 4 2.2 (0.5; 4) (IQR 1.6; 2.9) 16 1.7 (0.5; 9.5) (IQR 1.2; 2.5)
Bone age delay (yr) 12 1.3 (0.5; 4.1) (IQR 1; 1.7) 4 2.8 (0.5; 6.4) (IQR 2; 3.9) 16 1.4 (0.5; 6.4) (IQR 1; 2.6)
Target height (SDS) 16 20.2 (21.6; 1.5) (IQR –0.7; 0.3) 5 20.3 (21.5; 0.6) (IQR –0.6; 0.4) 21 20.3 (21.6; 1.5) (IQR –0.6; 0.4)
Height (SDS) 16 22.7 (24.3; 21.3) (IQR –3.7; 22.3) 5 22.2 (22.4; 22) (IQR –2.2; 22) 21 22.5 (24.3; 21.3) (IQR –3.5; 22)
Height velocity (SDS) 16 23( 24.1; 0.3) (IQR –3.3; 21.6) 5 23.3 (24.2; 0) (IQR –3.4; 23.2) 21 23.1 (24.2; 0.3) (IQR –3.4; 21.6)
Weight (SDS) 16 22.5 (24; 20.4) (IQR –3; 21.9) 5 20.7 (21.3; 1.1) (IQR –1.2; 20.3) 21 22.4 (24; 1.1) (IQR –2.8; 21)
BMI (SDS) 16 20.9 (23.7; 2.2) (IQR –1.5; 0.2) 5 1.3 (20.2; 4) (IQR –0.1; 1.7) 21 20.23 (23.7; 4) (IQR –1.1; 0.5)
GH peak (ng/mL) 16 3.2 (1.5; 23) (IQR 2; 6.7) 5 2.1 (0.5; 4.1) (IQR 0.9; 3.1) 21 3 (0.5; 23) (IQR 2; 5.5)
IGF-1 (ZS) 16 22.9 (25.1; 22) (IQR –4; 22.4) 5 24.8 (25; 24.1) (IQR –4.9; 24.4) 21 23.1 (25; 22) (IQR –4.4; 22.7)
CI: confidence interval 95%.
IQR: interquartile range.
GHD: growth hormone deficiency.
MPD: multiple pituitary deficiencies.
SDS: standard deviation score.
ZS: Z-score.
doi:10.1371/journal.pone.0016367.t001
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Main results
We analyzed the diagnostic delay and sensitivity for the GHRS
auxological criteria in the largest reported cohort of children seen
for PSIS with GHD since the publication of these criteria. We
studied the GHRS guidelines rather than other rules, such as the
Dutch consensus guidelines or the UK guidelines, because it has
been already demonstrated that both of these European
guidelines lack specificity [17,18,19] or sensitivity [17,19]. A
Dutch team recently proposed another algorithm to identify
children with short stature who require a diagnostic work-up, but
this algorithm did not target PSIS with GHD as a key diagnosis
[20]. We chose to study patients with GHD and PSIS because
they comprise a homogeneous population with a permanent
GHD, and because the real clinical significance of GHD without
PSIS (diagnosed by a low GH response after 2 pharmacological
stimulation tests and normal MRI) is a matter of debate today
[21].
In all, 71% of patients had a diagnostic delay greater than 1
year. Correct application of the GHRS auxological criteria could
have allowed diagnosis of these patients and the beginning of their
treatment 2 years earlier. Of the GHRS criteria, the most effective
for early and frequent diagnosis was height more than 1.5 SDS
below the target height and the criterion met by all patients was
height more than 2 SDS below the mean + height velocity over 1
year more than 1 SDS below the mean for chronological age.
Height velocity and distance to target height have already been
described by other teams as effective markers for detecting other
growth disorders, such as Turner’s syndrome, GHD and celiac
disease [17,22,23].
Distance to target height and height velocity are still underused
in routine practice [14]. Interestingly, height velocity is not
included in the UK consensus guideline [19,24,25] nor as a growth
monitoring indicator in the national French pediatric health
notebook. It is not provided by the World Health Organization
(WHO) growth charts after 24 months [19], not included in any
study evaluating the effectiveness of height-screening programs
[25], and was used by fewer than 50% of European pediatric
endocrinologists in a 2002 survey [14].
The specificity of each of the best criteria identified by our study
(height more than 1.5 SDS below the target height, as well as
height more than 2 SDS below the mean + height velocity over 1
year more than 1 SDS below the mean for chronological age)
could not be determined but can be compared indirectly with
those of other studies [17,22,23]. The specificity of the Dutch
guidelines for short stature was tested on a longitudinal growth
data of 870 children born in a geographical area of the
Netherlands [18]. Of the six criteria of the Dutch guidelines, the
criteria of height more than 21.3 SDS below the mean and of
height more than 21.3 SDS below the target height, which are
close to one of our best criteria, had a specificity of 94%.
Although it may be somewhat difficult to use all GHRS criteria
in routine practice to detect growth anomalies, our results for
patients with GHD and PSIS as well as results from a larger
population [22] indicate that distance to target height should be
used routinely as a warning sign for growth anomalies to select the
patients who require further investigation. It should replace height
for age which is relatively insensitive for the detection of clinically
relevant growth disorders [19].
Our work shows that GH peak is not enough to rule out a
diagnosis of GHD. Indeed, GHD had been ruled out for 2 (10%)
of the 21 patients included during their medical care because of
normal GH peaks, despite serum IGF-1 less than –2 SDS. This
observation supports the current modification of the use of GH
provocative tests in the evaluation of GHD [21,26,27,28].
Indeed, they are expensive, labor intensive, occasionally risky,
and their results not very reproducible [28,29,30]. Their use has
declined over the past two decades. Serum IGF-1, together with
the growth rate, provides high quality diagnoses that are
practical, simple and very accurate [30]. Patients suspected for
GHD, with a BMI between –2 and +2S D S ,w i t hv e r yl o wI G F - 1
levels should skip GH provocative tests and should be prescribed
a MRI [29,30].
Table 2. Individual analysis of auxological GHRS criteria.
Height
,23 SDS
Height
,21,5 SDS
below the
target height
Height ,22
SDS and
height velocity
,21 SDS*
Height ,22
SDS and height
diminution
.0,5 SDS**
Normal height
and height
velocity
,22 SDS*
Normal height
and height
velocity
,21,5 SDS***
At least
one of the
6 criterion
Criterion completed at
diagnosis n (%) (CI)
11 (52%)
(31–73)
19 (90%)
(77–100)
21 (100%)
(100–100)
11 (52%)
(31–73)
5 (24%)
(6–42)
4 (19%)
(2–36)
Age at criterion completion
(yr) median (range) (IQR)
1 (0,6; 10)
(0.7; 2.2)
1( 0 ;9 )
(0.5; 1.8)
2 (1; 9)
(1; 3.9)
3( 2 ;6 )
(3; 4.3)
3 (2; 6)
(3; 4)
3( 2 ;4 )
(2.7; 3.2)
1 (0; 4)
(0.6; 2)
Number of patients who completed
the criterion first n (%) (CI)
2 (18%)
(0–41)
16 (84%)
(67–100)
4 (19%)
(2–36)
0 (0%)
(0–0)
2 (40%)
(3–83)
1 (25%)
(0–67)
Potential reduction of diagnostic
delay among the patients who
completed the criterion (yr)
median (range) (IQR)
2 (0; 6.8)
(0.1; 3.3)
2.1 (0; 12.6)
(1.5; 2.9)
1.5 (0; 9.6)
(0; 3)
0 (0; 1.5)
(0; 0.3)
2 (0.6; 4.5)
(0.7; 2.1)
2.7 (0.5; 6.5)
(1.6; 4.2)
Potential reduction of diagnostic
delay among all patients (yr)
median (range) (IQR)
0 (0; 6.8)
(0; 2)
2 (0; 12.6)
(0.6, 2.8)
1.5 (0; 9.6)
(0; 3)
0 (0; 1.5)
(0; 0)
0 (0; 4.5)
(0; 0)
0 (0; 6.5)
(0; 0)
2.3 (0; 12.6)
(1.5; 3.6)
*over 1 year.
**over 1 year in children older than 2 years of age.
***over 2 years.
CI: confidence interval 95%.
IQR: interquartile range.
SDS: standard deviation score.
doi:10.1371/journal.pone.0016367.t002
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We used the national growth charts included in the French
health notebook, developed in 1979 [31]. In 2006, the WHO
multicentre growth reference study published growth charts for
healthy breastfed infants living in good hygiene conditions [32].
The comparison of the anthropometric measurements of French
children with the new WHO growth standards showed similarities
for the neonatal measurements but differed substantially thereaf-
ter, with French measurements (height, weight and BMI) lower
from 1 to 6 months and French height lower but BMI higher from
6 months to 5 years old [33]. The GHRS consensus guidelines do
not make it clear which growth charts should be used. Testing the
sensitivity of GHRS criteria by using WHO growth charts is thus
probably necessary. Our study was limited to a single center, a
design that can result in recruitment bias. The presence of such a
bias is supported by the mean age at diagnosis of symptomatic
PSIS in our cohort, 3.6 years, compared to those reported in the
literature, 4 to 9 years [5,7,12,13,15,21]. It is thus possible that
diagnostic delays are greater in the general population and that
application of the GHRS criteria would reduce diagnostic delays
still more than it would have in our patients.
Adoption and uncertain paternity are common, limiting utility
of the ‘‘target height’’ criterion. That is the reason why it may be
useful to consider the use of a combination of our two best criteria:
height more than 1.5 SDS below the target height and height
more than 2 SDS below the mean + height velocity over 1 year
more than 1 SDS below the mean for chronological age.
Unexpected findings
We were surprised by the high proportion (14%) of breech
presentation vs 4% in the general population in France [34], and
by the high proportion of cesareans (43%) vs 25% in the general
population in France [35]. Of patients with MPD, 20% were born
in breech presentation, and 80% (including all patients with
thyrotrophic insufficiency) were born by cesarean delivery. If we
incorporate in the analysis the six excluded patients with PSIS
diagnosed during the neonatal period, 22% of patients had breech
presentations and 56% cesarean births, for all six were born by
cesarean deliveries, three in breech presentation. We were not able
to identify a selection bias that could explain this unexpected
finding. The frequency of breech presentation and cesarean
delivery for GHD patients in the literature varies respectively from
7 to 60% and 30 to 40% [36,37,38]. TSH and/or ACTH
deficiency and/or GHD may play a role in labor or fetal mobility
and lead to breech presentation and/or cesarean delivery.
Although we certainly do not recommend a pituitary MRI for
all newborns by cesarean delivery or with breech presentations,
clinicians should be aware of this finding in determining which
newborns with hypoglycemia require a diagnostic workup for
GHD.
Perspectives
Screening rules based on growth monitoring are currently a
topic of debate [18,19,20]. Evidence-based strategies must be
tested, both for their sensitivity for early diagnosis in case-cohort
series of given target diseases (e.g., GHD, celiac disease, and
Turner’s syndrome) and for their specificity in healthy populations
[23,39]. The introduction of some of the GHRS criteria (especially
height more than 1.5 SDS below the target height and height
more than 2 SDS below the mean + height velocity over 1 year
more than 1 SDS below the mean for chronological age) would
probably be helpful for the early diagnosis of the target disease
here, PSIS with GHD. However, the precise specificity of these
criteria and their performance for the early diagnosis of other
target diseases involving growth monitoring must be tested.
Methods
Study design
This single-center retrospective case-cohort study included all
patients seen for PSIS with GHD by a senior pediatric
endocrinologist (R Brauner) from January 2000 to December
2007. During the study period, the local routine protocol called for
the systematic prescription of GH stimulation tests for all patients
seen for growth failure and for systematic MRI of the
hypothalamic-pituitary area of those with GHD (as defined
below). All patients whose computerized hospital chart or
discharge codes contained the words ‘‘growth hormone deficien-
cy’’ and ‘‘pituitary stalk interruption syndrome’’ were considered
for inclusion. The Institutional Review Committee (Comite ´d e
Protection des Personnes Ile de France III) stated that ‘‘this
research was found to conform to generally accepted scientific
principles and research ethical standards and to be in conformity
with the laws and regulations of France, where the research
experiment was performed.’’ Written informed consent of the
patients or their parents was not judged necessary for this kind of
retrospective study. The data of some of the patients included in
the present were previously used for other purposes [26,30].
Inclusion criteria
We included all patients seen consecutively for GHD and PSIS.
GHD was diagnosed by a GH peak of 10 ng/mL or less or
20 mIU/L or less after two pharmacological stimulation tests or a
very low level of insulin-like growth factor (IGF)-1 (less than 22
standard deviation scores (SDS)) [40]. PSIS was diagnosed by
MRI, according to the criteria described above. Patients with
GHD but with a normal MRI or an isolated hypoplastic anterior
pituitary gland were excluded, as well as adopted patients (because
perinatal history and parental heights were not available). Patients
with a diagnosis of PSIS in the neonatal period were also excluded
because their growth rate before diagnosis could not be calculated.
Collected data
Social, demographic, and medical data were extracted from the
medical report: sex, parental height, and perinatal history. Signs
observed before diagnosis and medical and growth records were
noted. Data related to the GHRS clinical and auxological criteria
were also extracted. During the neonatal period, these criteria are
hypoglycemia, prolonged jaundice, microphallus, or traumatic
delivery. In the post-neonatal period, they include severely short
stature, defined as a height more than 3 SDS below the mean;
height more than 1.5 SDS below the target height; height more
than 2 SDS below the mean and a height velocity during the
previous year more than 1 SDS below the mean for chronological
age, or a decrease in height SDS of more than 0.5 over 1 year in
children older than 2 years; in the absence of short stature, a
height velocity more than 2 SDS below the mean over 1 year or
more than 21.5 SD over 2 years [16].
Definitions
Target height was calculated from parental height [41] and
expressed in SDS. Microphallus was defined as a penis length of
2.5 cm or less (22 SDS) [12]. Height, weight, body mass index
(BMI, weight in kg/height in m
2) and height velocity were
expressed in SDS for chronological age [31,42]. Bone age was
evaluated by one of us (RB) according to the Greulich and Pyle
method [43]. Bone age delay was defined as the difference in years
Growth Hormone Deficiency: Screening Rules
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hormone deficiency was defined by thyroxin level less than
12 pmol/L and adrenocorticotrophin deficiency by basal blood
cortisol at 08.00 h less than 70 mg/L.
Analysis
We first analyzed population characteristics at diagnosis of PSIS
with GHD and then studied the medical and growth history,
symptoms, and clinical signs through diagnosis. Comparison of
each GHRS auxological criterion with growth charts allowed us to
establish the age at which each criterion was met, to class each
criterion in chronological order of fulfillment, and then to evaluate
the diagnostic delay, defined as the difference between the age at
which the earliest GHRS criterion was met and the age at
diagnosis of PSIS with GHD. We arbitrarily considered a
diagnostic delay of one year or more as late diagnosis. Finally,
we analyzed each GHRS criterion for how early and with what
frequency it was met and arbitrarily defined the most effective
criterion as the one that was most sensitive and earliest.
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